Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (1549)	3/3/2002 7:25:38 AM
From: mopgcw	Respond to of 7143

Genetronics Submits Phase II Head/Neck Cancer Data To FDA DOW JONES NEWSWIRES SAN DIEGO -- Genetronics Biomedical Corp. (GEB) has completed a comprehensive review of its oncology data and has submitted its Phase II head and neck cancer data to the Food and Drug Administration. In a news release, Genetronics said it expects to begin Phase III clinical trials shortly. The company said it also expects to sign a comprehensive licensing and supply agreement for the sales and marketing of the MedPulser Electroporation Therapy System with a pharmaceutical company by the end of this calendar year. Genetronics specializes in targeted intracellular delivery of drugs and genes, concentrating on drugs, vaccines, and gene therapy. Company Web Site: genetronics.com